Privately held Deciphera Pharmaceuticals LLC signed its first big pharma deal, licensing rights to four preclinical B-Raf kinase inhibitors to Eli Lilly and Co. for the development of oncology drugs.
See the rest here:
Assistant Managing Editor (BioWorld)
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.